<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) are a collection of <z:e sem="disease" ids="C1521860" disease_type="Disease or Syndrome" abbrv="">hematologic disorders</z:e> that affect older adults, and whose baseline characteristics and risk factors for evolution to <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and <z:hpo ids='HP_0011420'>death</z:hpo> have not been completely defined </plain></SENT>
<SENT sid="1" pm="."><plain>We analyzed a large unselected cohort of 214 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> from the University of Pittsburgh Network <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Registry in Western Pennsylvania </plain></SENT>
<SENT sid="2" pm="."><plain>Patients' follow-up was 22 months, at the end of which 72.9% of patients were dead </plain></SENT>
<SENT sid="3" pm="."><plain>Overall, the 36-month survival rate was 19.0% (95% CI: 14.0-24.5%); 22.4% (95% CI: 16.4-29.0%) for patients with lower-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>; and 5.0% (95% CI: 0.1-14.8%) for patients with higher-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (p = 0.0007) </plain></SENT>
<SENT sid="4" pm="."><plain>During follow-up, 32.9% of the patients developed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Family history of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and having  ≥5% blasts at diagnosis were statistically significant predictors for progression to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>A higher risk of <z:hpo ids='HP_0011420'>death</z:hpo> also was associated with age &gt;70 years and previous diagnosis of another <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>More than three cycles of chemotherapy sessions and a platelet count of ≥50 × 10(3)/mm(3) were inversely associated with <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>This study suggests the need to incorporate laboratory results such as percentage blasts and platelet counts as well as epidemiologic data on family history of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> in future outcome studies on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>